If Only My Father Could Choose to Deny the Holocaust
Alzheimer's progresses in a pattern that erodes the mind in reverse, stripping away recent memories first, then advancing into the regions that regulate emotion and suppress fear. Early memories, especially those charged with deep emotion, tend to last the longest.
So now, with his brain's defenses weakened, the horrors he experienced as a child in a Jewish ghetto in Poland surge through him unfiltered. They come without warning, intruding even in moments of joy, as if he's reliving them.
The growth of Holocaust denial and antisemitism presents a brutal irony. The people tormented by their memories can't forget, and too many of those who should remember choose not to do so.
My father is not alone in his suffering. A large study by researchers at the University of Haifa in Israel found that Holocaust survivors were about 21 percent more likely to develop dementia, probably owing to the lasting neurological and physiological effects of extreme trauma and deprivation.
My father was 11 when the Nazis invaded Poland, and he had to start wearing a yellow star of David on the front and back of his clothing so that it could be seen from both directions. He and about 200,000 Jews in Lodz were eventually sealed off behind walls and barbed wire. In the ghetto my father and his family faced starvation and disease, and were forced into labor. My father worked in a shoe factory that supplied the German military. Dozens of his family members were tortured and killed.
Want all of The Times? Subscribe.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
37 minutes ago
- Yahoo
‘I'm so strong': Film about electric shock use at Mass. center hopes to reach Sundance
As a teenager, Jennifer Msumba had 'very strong self-harm behaviors,' including putting her head through windows. Hoping to get her help, her parents sent her to a center in Massachusetts, where she was subjected to electric shocks daily as punishment. Nearly 25 years later, she's continuing to speak out — hoping a new documentary will expose the place that left her traumatized. 'That was like being unground in hell,' she recalled about her time at Judge Rotenberg Center (JRC) in Canton in the documentary's trailer. JRC, a special needs day and residential facility in Canton, has become known across the country for using electric shock devices, which are attached to the residents at all times, on people demonstrating self-injurious or aggressive behavior. It is the only facility in the country to use them and has been the center of many advocates' concerns for decades. 'This is 2025, and they are still shocking people,' she said in the documentary's trailer. 'It needs to end.' The JRC has said the device is 'lifesaving' and that it is important it 'remains available to those for whom all other treatment options have been tried and failed,' the JRC and the JRC Parents Association wrote in a statement after a 2023 court ruling that allowed the devices to continue to be used. The facility has said that its clients have had behaviors that result in 'profound physical injuries including blindness and mutilation' prior to using the devices. The clients have also injured family members and loved ones. 'Families turn to JRC after exhausting other options because of its record in successfully addressing the most challenging cases. Clients live in the community with appropriate monitoring, and their care is overseen by on-site physicians and nurses to maintain the highest standards of safety and treatment. The program operates under rigorous oversight from state agencies and the courts,' a statement read. As of 2024, there were more than 300 people who attend or live at JRC, and about 55 people were approved for the devices. Msumba daydreams of ninjas breaking into JRC to 'save everybody' and shut down the facility. 'But I don't have ninjas,' she said. Instead, she is making a documentary called 'The Fish Don't Care When It Rains,' which she hopes to submit to Sundance. 'I'm so strong,' she said in the documentary, looking out the car window at the facility she once felt trapped in. Msumba has autism and said that while her behaviors stopped while she was on the electric shock device, her 'behaviors weren't fixed.' 'They were just manifested differently, into explosions. I would hold it in and then all of a sudden explode,' she told the state Legislature's Joint Committee on Children, Families and Persons with Disabilities during a 2023 hearing about her experience attached to the devices at JRC. She lived at JRC from 2002 until 2009 and was on the shock devices for all seven years. At the beginning of her time there, she said she was shocked daily. 'Crying was also a behavior that I got in trouble for, so I had to cry in secret,' Msumba said in video testimony used in an FDA hearing. In March 2020, the U.S. Food and Drug Administration banned electrical stimulation devices (ESDs) used for self-injurious or aggressive behavior. But that decision was overturned. The FDA warned in its petition that the 'FDA determined that those devices present unreasonable and substantial risks of both physical and psychological injury.' 'The shocks cause pain that has been described as 'extremely painful,' 'excruciatingly painful,' 'like a dentist drilling on an un-anesthetized tooth,' like a 'bulging and a ruptured disc,' like 'a thousand bees stinging you in the same place for a few seconds,' and as 'the most painful thing I've ever experienced,'' the petition states. But it wasn't just the electric shocks that Msumba said traumatized her. She also was denied food and 'was one of those stripped of all my clothes, tied to a restraint board and forcefully scrubbed while male staff watched on the video monitors.' 'I did not consent to any of this treatment,' she said. The center had also taken guardianship away from her parents, the documentary trailer states. She has since left to live at a different placement in Florida, which she said has helped her. But when she arrived, she went back to her old self-harming behaviors. 'Instead of hurting me, they helped figure out why these things were happening and took the time to do so. They helped me learn to cope and self-regulate, [and] also allowed access to medication that I really needed,' she said. In 2021, Msumba released a book, 'Shouting At Leaves' regarding her time at the center. She also shares some of her story on TikTok. 'I have a real life now,' she said. In the documentary trailer, Msumba looks back on her time at JRC. 'I have no idea how I got through all that,' she said. But she also recognizes her accomplishments since then. Her own music is included throughout the documentary. Over the years, she's used vlogs to help her understand she needed to use different facial expressions when talking, rather than always looking mad. She also joined a church worship band to help her make friends. To help with the documentary, she also crowdfunded. A GoFundMe raised more than $10,000, which was their first goal to get the film funded. The second goal is to raise $20,000 to help 'get a rough cut to Sundance by September.' And the final goal is to raise $25,000 for other festivals and impact campaigns. 'Because of your support, we're now gearing up to film the final scenes of The Fish Don't Care When It Rains next month. This is huge,' the GoFundMe states. 'Every single dollar, share, and word of encouragement helped get us here. Thank you for being part of this movement.' She's hoping getting the documentary on the right platforms will finally bring 'real conversation' and change. 'They wildly underestimated me,' she said. More stories about JRC Sent to school that uses electric shocks, Mass. woman runs for office to protect others 'It's people like me': Protesters rally against electric shock devices at Mass. school FDA's proposed ban on shock devices used at Mass. school faces new battle Former student speaks out against electric shock devices used at Mass. facility DCF sends kids to controversial Mass. facility known for electric shock devices Read the original article on MassLive. Solve the daily Crossword
Yahoo
a day ago
- Yahoo
Controversial rapper slammed for calling LGBTQ+ identities ‘trauma response'
A rapper who has became more known for her controversial opinions than her music is under fire once again. Azealia Banks has sparked backlash for a recent social media post in which she called LGBTQ+ identities 'a trauma response.' 'Well being gay and transgender is not actually a natural thing. At all, it's a trauma response,' Banks, 34, wrote in an X post from Sunday, July 27. 'Science lied to you all and told you, you were normal but being homosexual and on the more extreme end — transgender in any regard is in fact — a trauma response," the rapper wrote. 'No one is born gay, and no one is born in the wrong body. You guys have mental disorders that science is doing you guys a major disservice by not medicating. Bet you didn't know that.' Social media users were quick to ridicule Banks, calling her words hateful, transphobic and scientifically inaccurate. 'Attraction to the same sex and living outside assigned gender roles aren't modern concepts. They've existed for as long as humans have recorded history, across cultures, continents, and centuries,' one X user commented. 'Being gay is 'unnatural' in the same way that a healthy woman of birthing age can be barren, or a hermaphrodite has genitals unaligned with either sex,' another comment read. 'Out of the ordinary, but definitely still a part of the human condition and nature at large. The trauma thing does not hold up.' Major health organizations have affirmed that sexual orientation is natural and not a conscious choice that someone makes. Planned Parenthood's website states that 'research shows that sexual orientation is likely caused partly by biological factors that start before birth.' Meanwhile the American Psychiatric Association and the American Psychological Association have found evidence 'that homosexuality is a normal variant of human sexual orientation as opposed to a mental disorder,' according to a study published by the National Institute of Health — therefore refuting Banks' claim. 'Well someone never bothered to advance their own education,' another X user wrote on the rapper's post. 'It's more ignorant than anything and admittedly embarrassing that you'd want to simplify our entire species down to the smallest boxes that even the entire animal kingdom doesn't follow,' they continued. 'I am embarrassed for and of you.' Banks, best known for her 2011 hit song '212,' has a history of sharing controversial thoughts on social media and has long been accused of homophobia and transphobia. In 2015, the rapper was caught calling a flight attendant a '(expletive) faggot' and, in 2016, was banned from X for making racist and homophobic comments about One Direction singer Zayn Malik. A more recent incident happened in 2020 when Banks posted a meme accusing gay people of 'appropriating horse culture,' MetroWeekly reported. Banks has also made transphobic remarks, most notably in 2021 when she she said that trans women are 'just gay boys on hormones using male aggression to force their ways into women's spaces,' PinkNews reported. However, in February 2025, Banks started to show support for the transgender community when she criticized author J. K. Rowling's views on trans women. 'All of the insane anti-trans paranoid people like @jk_rowling feel their femininity is threatened for whatever reason and try to mask that insecurity with 'science' like anyone is stupid and doesn't already know these things,' Banks wrote in an X post. In a follow-up post, Banks shared her experiences of watching her brother, who she said identifies as trans, struggle with their sexual identity. 'I have witnessed first hand the type of misery, pain, ostracism, suicide attempts, unnecessary and unwarranted abuse my mother doled out to my brother, the discomfort with his body,' Banks wrote. 'It's not a mental illness it's a spiritual thing.' More music content Original lead singer of iconic metal band dies at 69 Linkin Park to play two shows in Boston, here's how to buy last-minute tickets Popular band's frontman sued over 2019 post urging hurricane relief donations Rock star eats at Northeast diner — twice: 'It's a great day' All the fall 2025 music acts and performances coming to The Big E Read the original article on MassLive. Solve the daily Crossword
Yahoo
2 days ago
- Yahoo
Anavex's blarcasemine nets win in Phase IIb/III Alzheimer's extension study
In another potential win for patients with early-stage Alzheimer's disease, Anavex Life Science's precision medicine blarcasemine has met its primary endpoints in a late-stage trial. Announced at the 2025 Alzheimer's Association International Conference (AAIC), results of the Phase IIb/III ATTENTION-AD (NCT04314934) extension study revealed that blarcasemine, dubbed internally as Anavex 2-73, improved patients' cognitive function by 36.3%, as measured by the Alzheimer's Disease Assessment Scale-Cognitive 13-item (ADAS-COG13) scale. The oral autophagy reactivator also improved daily functioning by 27.6% according to the Clinical Dementia Rating Scale Sum of Boxes (CDR-SB) scale, highlighting the drug's capacity to stave off symptoms of Alzheimer's in the disease's early stages. Like other Alzheimer's-targeting disease modifying therapies (DMTs) on the market, blarcasemine worked best in patients who began taking the drug early, with early initiation offering patients 19.5 months of 'time saved'. The 'time saved' concept describes the period in which a drug can stave off disease progression and allow patients to maintain both functionality and independence. Alzheimer's market competition heats up In recent years, the once stagnant Alzheimer's market has been ignited — primarily driven by the approvals of key anti-amyloid beta monoclonal antibodies (Aβ mAbs) such as Biogen & Eisai's Leqembi (lecanemab) and Eli Lilly's Kisunla (donanemab), which were given FDA greenlights in 2023 and 2024, respectively. This has driven the market's value significantly, with a forecast from GlobalData, parent company of Clinical Trials Arena, estimating it will be worth $19.3bn in the 8 major markets (8MM includes the US, Germany, France, Italy, Spain, the UK, Japan and China) by 2033. According to a report by Globaldata, these therapies are set to dominate the Alzheimer's market, with Kisunla and Leqembi forecasted to rake in $2bn and $3.5bn, respectively, in the 8MMs. However, neurology analyst at GlobalData, Phillipa Salter noted that anti-Aβ mAbs have been difficult to integrate into clinical practice due to 'their association with significant side effects, including amyloid-related imaging abnormalities (ARIA).' 'They are also only modestly effective, so having alternative treatment options that don't target amyloid will be welcomed in the AD space,' Salter commented. Salter added: 'Significant opportunity therefore exists for Anavex 2-73 with its convenient oral dosing and favourable safety profile.' Instead of targeting and breaking down tau and beta amyloid (Aβ) plaques like Kisunla and Leqembi, Anavex 2-73 works to restore cellular autophagy — a natural process which becomes faulty in early Alzheimer's disease pathology before plaques begin to form. By targeting a mechanism involved in the very early stages of Alzheimer's, blarcasemine differentiates itself from rival therapies at market. "Anavex's blarcasemine nets win in Phase IIb/III Alzheimer's extension study" was originally created and published by Clinical Trials Arena, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Sign in to access your portfolio
